Research programme: ion channel inhibitors - Xenon Pharmaceuticals
Alternative Names: Nav1.2/1.6 inhibitors - Xenon Pharmaceuticals; Nav1.6 inhibitors - Xenon Pharmaceuticals; Sodium channel inhibitors - Xenon PharmaceuticalsLatest Information Update: 28 Jan 2024
At a glance
- Originator Xenon Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action NAV1.2 voltage-gated sodium channel inhibitors; Nav1.6 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Epilepsy
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for research development in Epilepsy in Canada
- 31 Dec 2021 Xenon Pharmaceuticals has patent protection and patents pending for Nav1.2 and or Nav1.6 inhibitors in US and outside as of December 2021
- 02 Dec 2019 Neurocrine Biosciences in-licenses ion channel inhibitors from Xenon Pharmaceuticals